'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Research ADCs
- Research Apoptosis
- Research B cell
- Research BRAF
- Research HDIs
- Research HER Pathways
- Research MET
- Research VEGF
- Why is the VEGF ligand essential throughout tumor development?
- What are the strategies for inhibiting the VEGF pathway?
- What are the effects of direct VEGF ligand inhibition?
- Why is continued VEGF inhibition important?
- Why do tumors progress?
- The role of VEGF across tumor types
- Slide decks and videos
- Glossary
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Clinical Trials
- Future Directions
- Antibody-Drug conjugates
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Glycoengineered Antibodies
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Non-Antibody Biologics
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Targeted Small Molecules
- Apoptosis
- Resisting apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MAPK Signaling
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- PI3K/Akt/mTOR Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- B-cell Surface Proteins
- Glossary
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Angiogenic Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Antibody-Drug conjugates
Video
Full VEGF & angiogenesis
View video now
Slides
The role of VEGF in colorectal cancer (CRC)
View SlidesLinks
Share
VEGF and prognosis in colorectal cancer
Evidence from numerous studies and analyses points to vascular endothelial growth factor (VEGF) and angiogenesis as prognostic factors in colorectal cancer. For information on a particular outcome that has been correlated with VEGF expression, click on the links in the table below.
| Outcome | Study Type and Size | Source |
|---|---|---|
| Poor survival | Clinical study (N=60) Meta-analysis of 27 studies |
Ishigami et al, Br J Cancer, 19981 Des Guetz et al, Br J Cancer, 20062 |
| Increased risk of relapse | Meta-analysis of 27 studies | Des Guetz et al, Br J Cancer, 20062 |
| Metastasis | Clinical study (N=133) Clinical study (N=60) Clinical study (N=31) |
Tanigawa et al, Cancer Res, 19973 Ishigami et al, Br J Cancer, 19981 Kuramochi et al, Clin Cancer Res, 20064 |
|
Tumor invasion and lymph node involvement |
Clinical study (N=72) Clinical study (N=90) |
Ottaiano et al, Clin Cancer Res, 20065 Saad et al, Mod Pathol, 20066 |
References:
- 1.
- Ishigami SI, Arii S, Furutani M, et al. Br J Cancer. 1998;78:1379-1384. PMID: 9823983
- 2.
- Des Guetz G, Uzzan B, Nicolas P, et al. Br J Cancer. 2006;94:1823-1832. PMID: 16773076
- 3.
- Tanigawa N, Amaya H, Matsumura M, et al. Cancer Res.
1997;57:1043-1046. PMID: 9067267 - 4.
- Kuramochi H, Hayashi K, Uchida K, et al. Clin Cancer Res. 2006;12:29-33. PMID: 16397020
- 5.
- Ottaiano A, Franco R, Talamanca AA, et al. Clin Cancer Res. 2006;12:2795-2803. PMID: 16675573
- 6.
- Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF. Mod Pathol. 2006;19:1317-1323. PMID: 16799477